PMS-ZOLMITRIPTAN TABLET
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
15-04-2020
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
ZOLMITRIPTAN
Tillgänglig från:
PHARMASCIENCE INC
ATC-kod:
N02CC03
INN (International namn):
ZOLMITRIPTAN
Dos:
2.5MG
Läkemedelsform:
TABLET
Sammansättning:
ZOLMITRIPTAN 2.5MG
Administreringssätt:
ORAL
Enheter i paketet:
6/30
Receptbelagda typ:
Prescription
Terapiområde:
SELECTIVE SEROTONIN AGONISTS
Produktsammanfattning:
Active ingredient group (AIG) number: 0134381001; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2011-06-07
Produktens egenskaper
PRODUCT MONOGRAPH
PR
PMS-ZOLMITRIPTAN
Zolmitriptan Film-Coated Tablets, House Standard
2.5 mg
PR
PMS-ZOLMITRIPTAN ODT
Zolmitriptan Orally Dispersible Tablets, House Standard
2.5 mg
5-HT1 RECEPTOR AGONIST
MIGRAINE THERAPY
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Québec
H4P 2T4
www.pharmascience.com
DATE OF REVISION:
April 15, 2020
Submission Control No.: 237071
_ _
_pms-ZOLMITRIPTAN and pms-ZOLMITRIPTAN ODT Product Monograph _
_Page 2 of 41 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................18
DOSAGE AND ADMINISTRATION
..............................................................................20
OVERDOSAGE
................................................................................................................21
ACTION AND CLINICAL PHARMACOLOGY
............................................................22
STORAGE AND STABILITY
..........................................................................................25
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................25
PART II: SCIENTIFIC INFORMATION
...............................................................................26
PHARMACEUTICAL INFORMATION
..........................................................................26
CLINICAL TRIALS
....................
Läs hela dokumentet
